Skip to main content
. 2017 Aug 17;175(12):2219–2230. doi: 10.1111/bph.13957

Figure 3.

Figure 3

Structures of subtype‐selective P2X receptor antagonists. The compounds IP5I and RO‐85 can discriminate between P2X3 homomers and P2X2/3 heteromers. The orally bioavailable compound AF‐219 is currently tested in Phase III clinical trials for hypersensitized C‐fibre afferents and refractory chronic cough.